Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus

LONDON, March 24, 2014 /PRNewswire/ --

On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. During the session gains in the Utilities, Materials and Energy sectors positively impacted the broader market, while significant retraction came in from Health Care, Consumer Discretionary and Information Technology sectors. The S&P 500 Heath Care Sector Index finished the day at 675.70, down 1.54%, while the same has gained 5.90% in the last three months. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), StemCells Inc. (NASDAQ: STEM), Dendreon Corp. (NASDAQ: DNDN) and Vivus Inc. (NASDAQ: VVUS). Free technical research on EXEL, STEM, DNDN and VVUS can be downloaded upon signing up at:

http://www.investor-edge.com/443-register


Shares in Exelixis Inc. fell by 3.23% to finish day at $6.29. A total of 4.10 million shares were traded, which is above the three months average volume of 3.28 million. The company's shares oscillated between $6.18 and $6.61 during the session. Exelixis Inc.'s shares traded flat in the previous three trading sessions and have lost 10.40% in the last one month, while the shares gained 2.61% on YTD basis. The company's shares are trading below their 50-day moving average. Exelixis Inc.'s 50-day moving average of $7.10 is above the 200-day moving average of $5.75. Moreover, the stock is trading at an Relative Strength Index (RSI) of 39.55. Sign up today to read free research on EXEL at:

http://www.investor-edge.com/443-EXEL-24Mar2014.pdf


On Friday, shares in StemCells Inc. recorded a trading volume of 2.08 million shares, as compared with a three months average volume of 1.01 million shares. The stock ended the day at $1.50, down 0.66% and at an intraday range of $1.44 and $1.55. StemCells Inc.'s shares have gained 2.04% in the previous three trading sessions, 1.35% in the last one month and 21.95% on YTD basis. The company's shares are trading at their 50-day moving average. StemCells Inc.'s 200-day moving average of $1.51 is above the 50-day moving average of $1.50. Furthermore, the stock is trading at an RSI of 51.99. Sign up today to read free research on STEM at:

http://www.investor-edge.com/443-STEM-24Mar2014.pdf


Shares in Dendreon Corp. gained 0.67%, closing the day at $3.02. The stock recorded trading volume of 4.26 million shares as compared to a three months average volume of 4.10 million shares. The stock fluctuated between $2.97 and $3.03 during the trading session. Dendreon Corp.'s shares have declined 0.66% in the previous three trading sessions, while the stock has gained 1.68% in the last one month and 1.00% on YTD basis. The company's stock is trading above its 50-day moving average. Dendreon Corp.'s 200-day moving average of $3.24 is above the 50-day moving average of $2.96. Moreover, the stock is trading at an RSI of 52.46. Sign up today to read free research on DNDN at:

http://www.investor-edge.com/443-DNDN-24Mar2014.pdf


Vivus Inc.'s shares recorded a trading volume of 7.85 million shares, as compared with a three months average volume of 3.04 million shares. The stock ended the day at $5.84, down 2.01% and recorded an intraday range of $5.78 and $6.06. Vivus Inc.'s shares have fallen by 4.26% in the previous three trading sessions, 13.74% in the last one month and 35.68% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $7.05 and $10.24, respectively. Furthermore, the stock is trading at an RSI of 34.58. Sign up today to read free research on VVUS at:

http://www.investor-edge.com/443-VVUS-24Mar2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://Investor-Edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED